Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101 [Seeking Alpha]
Century Therapeutics, Inc. (IPSC)
Company Research
Source: Seeking Alpha
of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029. Initiation of phase 1 CALiPSO-1 study, using CNTY-101 for patients with systemic lupus erythematosus, is expected in the 1st half of 2024; Data from this study is to be released 2nd half of 2024. A highly important thing about this company would be the Allo-Evasion technology incorporated into the iPSC-derived cell therapies, which not only improves the safety of patients but could mean improved responses. Century Therapeutics, Inc. NASDAQ: IPSC ) is a very interesting cell therapy biotech, especially with the accomplishments it has been able to make thus far. That's because it released positive interim data as a poster presentation at the
Show less
Read more
Impact Snapshot
Event Time:
IPSC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSC alerts
High impacting Century Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IPSC
News
- Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific OfficerGlobeNewswire
- Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at HC Wainwright from $11.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Century Therapeutics, Inc. (NASDAQ: IPSC) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
- Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
IPSC
Earnings
- 5/9/24 - Beat
IPSC
Sec Filings
- 9/26/24 - Form 8-K
- 9/16/24 - Form 4
- 8/8/24 - Form 8-K
- IPSC's page on the SEC website